Cardiol Therapeutics
CRDL
32 hedge funds and large institutions have $6.02M invested in Cardiol Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 6 closing their positions.
2,150% more call options, than puts
Call options by funds: $45K | Put options by funds: $2K
4% more capital invested
Capital invested by funds: $5.78M → $6.02M (+$242K)
0.76% more ownership
Funds ownership: 9.86% → 10.62% (+0.76%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
9% less funds holding
Funds holding: 35 → 32 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
+$400K |
| 2 |
LSA
Lion Street Advisors
Austin,
Texas
|
+$164K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$25.5K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$9.48K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$2.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AXS Investments
Port Chester,
New York
|
-$64.5K |
| 2 |
FIA
FNY Investment Advisers
New York
|
-$30K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$13.4K |
| 4 |
MA
MONECO Advisors
Fairfield,
Connecticut
|
-$12.5K |
| 5 |
HF
HRT Financial
New York
|
-$11K |
CRDL Hedge Fund Activity: Q4 2023 in Review
32 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q4 2023, worth a combined $6.02M — up 4.2% from $5.78M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CRDL and 3 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Tejara Capital, adding an estimated $400K. The largest seller was AXS Investments, cutting an estimated $64.5K.
- 32 institutional investors held Cardiol Therapeutics (CRDL) as of Q4 2023, down from 35 in Q3 2023.
- Funds reported $6.02M of Cardiol Therapeutics stock for Q4 2023, up 4.2% quarter-over-quarter.
- 3 funds opened new Cardiol Therapeutics positions in Q4 2023 and 6 closed out, a net change of -3 holders.
- The largest Cardiol Therapeutics buyer in Q4 2023 was Tejara Capital, an estimated $400K added.
- The largest Cardiol Therapeutics seller in Q4 2023 was AXS Investments, an estimated $64.5K sold.
Based on aggregated 13F filings for Q4 2023.